Medication info
Ricastar Capsule 150mg

(Pregabalin)

Ricastar Capsule 150mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
(Co., Ltd.) Theragen Etex
Appearance
A white hard capsule filled with white powder.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201601186 · Approved 2016.02.29 · Insurance code 698503380

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
(Co., Ltd.) Theragen Etex

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used for the treatment of peripheral and central neuropathic pain in adults. Additionally, it is effective as an adjunct for partial seizures in adults with epilepsy. It is also utilized to treat fibromyalgia. The main indications include neuropathic pain, epilepsy, and fibromyalgia. It helps improve symptoms of various neurological disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys in unchanged form. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function ≥60 mL/min: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: The supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or behavior, so it is important to inform medical staff immediately if symptoms of depression or mood changes appear during treatment. Patients with an allergy to pregabalin or any ingredient of this medication should not take it. Diabetic patients may need to adjust the dosage of blood sugar control medications due to weight gain after taking this drug. If symptoms of angioedema, such as swelling of the face or mouth, occur, the medication should be stopped immediately. Elderly patients should note that this medication may cause dizziness, drowsiness, loss of consciousness, and confusion. Transient visual disturbances or changes in vision may occur; if symptoms appear, consult a physician. Suddenly stopping this medication may result in withdrawal symptoms such as insomnia, headaches, anxiety, depression, and seizures, so dosage adjustment should follow a physician's guidance. Patients with a history of substance abuse should be particularly cautious when taking this medication, observing for signs of misuse or dependence. Patients with impaired renal function may require dose adjustments. Patients with heart disease are advised to use this medication carefully due to the risk of congestive heart failure. Caution is advised when taking this medication with opioid analgesics due to the potential for increased central nervous system depression. This medication may cause dizziness and drowsiness, so care should be taken when driving or operating hazardous machinery. During early pregnancy, the risk of congenital malformations in the fetus is present, so it is generally advised that pregnant women do not take this medication. Women of childbearing age should use effective contraception. Breastfeeding women should consult with a doctor regarding the interruption of breastfeeding or the discontinuation of medication, as this drug can be passed into breast milk and may affect the infant. In the case of overdose, symptoms such as drowsiness, confusion, depression, and seizures may occur, requiring immediate medical attention. This medication should be kept out of reach of children, and changing the container for storage may lead to accidents and deterioration of quality.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 205 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • respiratory diseases
  • neurological disorders
  • kidney impairment
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • agitation
  • mood instability
  • emotional blunting
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive dysfunction
  • nystagmus
  • language disorders
  • myotonia
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field deficits
  • photophobia
  • dry eyes
  • ocular edema
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • ocular irritation
  • mydriasis
  • during vibration
  • changes in depth perception of vision
  • strabismus
  • brightness in vision
  • dizziness
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle twitching
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • elevated serum creatine phosphokinase
  • increased aspartate aminotransferase
  • elevated blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • states of confusion
  • agitation
  • restlessness
  • exacerbation of convulsions
  • ataxia
  • speech disorders
  • hematochezia
  • elevated BUN
  • tinnitus
  • skin disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The storage temperature should be maintained between 15 to 30 degrees Celsius. Proper storage helps maintain the drug's effectiveness.

Appearance and packaging

Appearance

A white hard capsule filled with white powder.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.